Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$40.59M$40.59Mderived−0.5% vs Q4 2024 Net Income-$2.95M-$2.95MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$29,469,000−3.5% Operating Incomederived$38,000−99.1% Operating Cash Flowderived-$9,184,000N/M Free Cash Flowderived-$9,184,000N/M Margins · derivedGross margin72.6%−2.3 pt vs Q4 2024
Operating margin0.1%−10.1 pt vs Q4 2024
Net margin-7.3%−16.3 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end